Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIDE cardiovascular outcomes trial in type 2 diabetes
2008-005030-73Phase 3Terminated
- Sponsor
- GSK
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rosiglitazone, pioglitazone and cholecalciferol in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by GSK. Primary endpoint: Composite cardiovascular primary outcome. Started Sep 2009; status: terminated.
02
Drugs
rosiglitazonepioglitazonecholecalciferol
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-005030-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005030-73.